Global manufacturing and commodity demand has shifted again, with Taiwan and China still exporting strongly in AI, semiconductors and broader technology. That keeps growth stories very much alive. Investors who like fast growing stocks with high insider ownership may see this as a chance to focus on companies where both analysts and management currently hold optimistic views. This article highlights three such stocks from the screener.
The stocks covered below are just a starting sample, and the full screen surfaced 99 more companies where growth expectations and insider alignment are telling their own compelling stories. If you want to identify and analyze the highest conviction setups with strong insider backing, head straight into the Fast Growing Stocks With High Insider Ownership screener.
Predictive Discovery (ASX:PDI)
Overview: Predictive Discovery is a West African gold company focused on finding and developing gold reserves, with its flagship Bankan Gold project in north east Guinea and operations run from South Perth, Australia. The business is building a portfolio that combines producing mines with Bankan as a major growth project.
Market Cap: A$3.75b
Investors looking at growth and insider alignment may find Predictive Discovery interesting because it is building a larger West African gold platform after its merger with Robex, with two producing mines and the Bankan project under way. Recent updates point to strong throughput and recoveries at the Kiniero mine and meaningful production from both Kiniero and Nampala, while free cash flow from these assets is helping fund Bankan development. The story is not without risk, including permitting uncertainty in Guinea, a shorter cash runway, a history of losses and operations in higher risk jurisdictions. Analysts have published research that sets out a potential path to profitability within three years and a higher price target than today’s share price, and recent governance changes suggest an active approach to shaping the next phase.
Predictive Discovery now combines two producing West African mines with the Bankan growth project. However, the full picture of cash generation, funding needs and political risk is easy to miss. Get the 2 key rewards and 3 important warning signs (2 are major!)
Build your own insider backed growth shortlist
Predictive Discovery and the other two stocks in this article all surfaced from a single Simply Wall St screen, but the real edge comes from tailoring the filters to what matters most to you. Use our customisable Screener to mix growth, quality, valuation and risk checks into your own shortlist, or tap into any of our ready made Investing Ideas for a curated starting point.
Telix Pharmaceuticals (ASX:TLX)
Overview: Telix Pharmaceuticals is a commercial stage biopharmaceutical company that develops and sells radiopharmaceuticals, which are precision imaging agents and therapies used to detect and treat cancers such as prostate, kidney and brain tumours across multiple countries.
Operations: Telix generates most of its revenue from Precision Medicine at about US$621.9 million, with additional contributions from Manufacturing Solutions at about US$245.1 million and Therapeutics at about US$9.3 million, offset by inter segment eliminations.
Market Cap: A$5.5b
Telix Pharmaceuticals sits at the intersection of fast growing cancer imaging revenue and a maturing radiopharmaceutical therapy pipeline, which is why it appears in a growth and insider ownership screen. The core Illuccix and Gozellix franchise is supported by fresh news flow, including Phase 3 progress for TLX591 and TLX250, new manufacturing capacity in Melbourne and a collaboration with Regeneron that brought in an initial US$40 million payment. At the same time, Telix is still loss making, carries higher funding risk, faces pricing pressure in PSMA imaging and is exposed to clinical and regulatory setbacks that could slow the path to profitability. For investors comfortable with that trade off, the mix of revenue momentum and potential pipeline upside may warrant a closer look.
Telix Pharmaceuticals sits at a rare intersection of rising cancer imaging revenue and an advancing therapy pipeline that the market may not fully appreciate yet. Read the analyst forecasts for Telix Pharmaceuticals to see what expectations might be missing.
GemLife Communities Group (ASX:GLF)
Overview: GemLife Communities Group develops, builds, owns and runs resort style land lease communities for Australians over 50, combining new home sales with long term management of shared facilities and services across its sites.
Operations: GemLife Communities Group generates most of its revenue in Australia from Development at about A$259.8 million, with Community Operations contributing about A$21.9 million.
Market Cap: A$1.69b
GemLife Communities Group provides exposure to Australia’s growing over 50s downsizer market, with a vertically integrated model, a pipeline of around 8,300 homesites extending for more than 10 years, and recurring site fees that move with CPI or a 3.5% floor. Analysts are currently optimistic on earnings and revenue growth, and the stock is trading well below some fair value estimates. However, high leverage, weaker cash flow cover and a large one off loss in 2025 indicate that growth involves meaningful risk. Together with a relatively new board and an upcoming results release on 24 August 2026, this is a stock where both the potential upside and the execution risk remain in focus.
GemLife Communities Group looks like growth is stretching far beyond its current pricing, with that long homesite pipeline and CPI linked fees raising fresh questions about what the market might be missing. The analyst forecasts for GemLife Communities Group could reveal the one factor that flips the story.
Seeking Alternatives Before Momentum Flies Past?
Fresh stock ideas do not stay under the radar for long. Screens fill up as momentum builds and potential breakouts get caught by the crowd. Consider researching opportunities early.
- Look for companies where strong balance sheets and solid fundamentals could support the next leg of momentum with the list of solid balance sheet and fundamentals (19 results).
- Combine potential yield and stability by scanning high payout candidates that might hold up when others drop using the 4 dividend fortresses.
- Track early movers in the next computing shift while these stocks are still under the radar for now through the 26 quantum computing stocks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com